Darwin Global Management »

Aeglea Biotherapeutics shares owned by Darwin Global Management

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $10M 452k 22.71
2024-03-31 $18M 473k 37.93

More positions owned by Darwin Global Management

Cytokinetics Com New (CYTK)
Insmed Com Par $.01 (INSM)
Vaxcyte (PCVX)
Geron Corporation (GERN)
Keros Therapeutics (KROS)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Spyre Therapeutics Com New (SYRE)
Avidity Biosciences Ord (RNA)
Elevation Oncology (ELEV)

View all positions for Darwin Global Management

Top funds holding Aeglea Biotherapeutics

Fairmount Funds Management
Perceptive Advisors
VR Adviser
Braidwell
BlackRock
Commodore Capital
Vanguard Group
Deep Track Capital
State Street Corporation
Assenagon Asset Management
Goldman Sachs Group
Geode Capital Management
Franklin Resources
Citadel Advisors
Boxer Capital

View all funds holding Aeglea Biotherapeutics